NEW YORK (GenomeWeb) — Agendia today announced a partnership with GeneCast Biotechnology to make its breast cancer tests available in China.

Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers. Local physicians will be able to send patient samples to GeneCast's oncology laboratory for testing, the firms said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.